Alzinova AB Logo

Alzinova AB

Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.

ALZ | ST

Overview

Corporate Details

ISIN(s):
SE0007413455
LEI:
549300K3IMVT20EK2S13
Country:
Sweden
Address:
Pepparedsleden 1, 431 83 MÖLNDAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alzinova AB is a clinical-stage biopharmaceutical company specializing in the development of disease-modifying treatments for Alzheimer's disease. The company's research is centered on its proprietary AβCC Peptide™ technology, which enables the development of immunotherapies that specifically target neurotoxic amyloid-beta oligomers, a central cause of the disease. Alzinova's pipeline includes both active immunotherapies (vaccines) and passive immunotherapies (antibodies). Its lead candidate, ALZ-101, is a therapeutic vaccine in clinical development designed to be a highly specific treatment to prevent or slow the progression of Alzheimer's disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Alzinova AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alzinova AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alzinova AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-03 Tord Evert Sigfried Labuda Other Other 1,000,000 260,000.00 SEK
2025-04-03 Tord Evert Sigfried Labuda Other Buy 10,000 18,800.00 SEK
2025-04-02 Tord Evert Sigfried Labuda Other Buy 20,000 40,000.00 SEK
2024-12-16 Erik Kullgren Other Buy 10,000 34,400.00 SEK

Peer Companies

Company Country Ticker View
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea 204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary GWPH

Talk to a Data Expert

Have a question? We'll get back to you promptly.